-
Consensus Rating
HoldBased on 28 Analyst Ratings
-
Consensus Price Target
$70.0010194.12% Upside
Hepion Pharmaceuticals, Inc. Frequently Asked Questions
-
What analysts cover Hepion Pharmaceuticals, Inc.?
Hepion Pharmaceuticals, Inc. has been rated by research analysts at Cantor Fitzgerald in the past 90 days.